We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies the Term ‘Outsourcing Facility’ and Requirements for 503A Compounders
FDA Clarifies the Term ‘Outsourcing Facility’ and Requirements for 503A Compounders
As part of its increased focus on drug compounding, the FDA issued a final guidance clarifying the term “outsourcing facility” and detailing requirements for compounders operating under 503A that are next to an outsourcing facility.